NasdaqGM:ALT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. More Details


Snowflake Analysis

Excellent balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Altimmune's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALT is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: ALT's weekly volatility has decreased from 24% to 18% over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

17.2%

ALT

2.8%

US Biotechs

1.5%

US Market


1 Year Return

555.9%

ALT

27.3%

US Biotechs

22.3%

US Market

Return vs Industry: ALT exceeded the US Biotechs industry which returned 27.2% over the past year.

Return vs Market: ALT exceeded the US Market which returned 22.1% over the past year.


Shareholder returns

ALTIndustryMarket
7 Day17.2%2.8%1.5%
30 Day-1.4%7.8%8.8%
90 Day-0.8%17.5%10.8%
1 Year555.9%555.9%29.5%27.3%25.1%22.3%
3 Year-76.4%-76.4%26.5%20.1%49.5%39.6%
5 Yearn/a21.0%12.7%105.8%83.3%

Long-Term Price Volatility Vs. Market

How volatile is Altimmune's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Altimmune undervalued compared to its fair value and its price relative to the market?

2.03x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ALT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ALT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ALT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALT is good value based on its PB Ratio (2x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Altimmune forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

60.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: ALT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ALT's is expected to become profitable in the next 3 years.

Revenue vs Market: ALT's revenue (48.5% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: ALT's revenue (48.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Altimmune performed over the past 5 years?

-16.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALT is currently unprofitable.

Growing Profit Margin: ALT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALT is unprofitable, and losses have increased over the past 5 years at a rate of 16.4% per year.

Accelerating Growth: Unable to compare ALT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.8%).


Return on Equity

High ROE: ALT has a negative Return on Equity (-21.29%), as it is currently unprofitable.


Next Steps

Financial Health

How is Altimmune's financial position?


Financial Position Analysis

Short Term Liabilities: ALT's short term assets ($218.1M) exceed its short term liabilities ($6.3M).

Long Term Liabilities: ALT's short term assets ($218.1M) exceed its long term liabilities ($27.0M).


Debt to Equity History and Analysis

Debt Level: ALT is debt free.

Reducing Debt: ALT has no debt compared to 5 years ago when its debt to equity ratio was 3.2%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ALT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Altimmune current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Vipin Garg (62 yo)

2.08yrs

Tenure

US$566,631

Compensation

Dr. Vipin K. Garg, Ph.D. has been President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg served as Advisor of Neos Therapeutics, Inc. since June 27, 2018 until...


CEO Compensation Analysis

Compensation vs Market: Vipin's total compensation ($USD566.63K) is below average for companies of similar size in the US market ($USD1.79M).

Compensation vs Earnings: Vipin's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Vipin Garg
President2.08yrsUS$566.63k0.97%
$ 3.9m
William Brown
CFO & Principal Accounting Officer2.58yrsUS$594.72k0.049%
$ 197.0k
Matthew Harris
Chief Medical Officer1.42yrsUS$542.62k0.012%
$ 50.2k
Bertrand Georges
Chief Technology Officer3.58yrsno datano data
M. Roberts
Chief Scientific Officer8yrsUS$290.39k0.029%
$ 116.0k
José Ochoa
Chief Business Officer2.42yrsno datano data

2.5yrs

Average Tenure

61.5yo

Average Age

Experienced Management: ALT's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Vipin Garg
President2.08yrsUS$566.63k0.97%
$ 3.9m
Mitchel Sayare
Independent Chairman2.92yrsUS$121.89k0.080%
$ 325.1k
John Gill
Independent Director16.33yrsUS$85.43k0.060%
$ 241.9k
David Drutz
Independent Director3.58yrsUS$92.43k0.055%
$ 221.1k
Philip Hodges
Independent Director3.58yrsUS$95.93k0.11%
$ 447.7k
John Petricciani
Member of Scientific Advisory Boardno datano datano data
Richard Whitley
Member of Scientific Advisory Boardno datano datano data
Klaus Schafer
Independent Director8.42yrsUS$85.93k0.021%
$ 85.1k
Wayne Pisano
Independent Director2.33yrsUS$92.93k0.026%
$ 104.8k
Diane Jorkasky
Independent Director0.58yrno data0%
$ 0

3.3yrs

Average Tenure

69yo

Average Age

Experienced Board: ALT's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 119.1%.


Top Shareholders

Company Information

Altimmune, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Altimmune, Inc.
  • Ticker: ALT
  • Exchange: NasdaqGM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$405.609m
  • Shares outstanding: 32.90m
  • Website: https://altimmune.com

Number of Employees


Location

  • Altimmune, Inc.
  • 910 Clopper Road
  • Suite 201S
  • Gaithersburg
  • Maryland
  • 20878
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALTNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDMay 2017
3G0DB (Deutsche Boerse AG)YesCommon SharesDEEURMay 2017
0A4CLSE (London Stock Exchange)YesCommon SharesGBUSDMay 2017

Biography

Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/05 00:18
End of Day Share Price2020/12/04 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.